Procaps Group S.A.

PROC

LU2376511205

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:29:12 18/05/2024 am IST			5-day change	1st Jan Change
2.66 ^USD	+3.10%		-2.21%	-34.64%

01/05	Procaps Group S.A. Provides Earnings Guidance for the Year Ended December 31, 2023	CI
04/03	Procaps Group S.A. Announces Formation of Strategic Committee to Explore Value Creation Alternatives	CI

Procaps Group S.A. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2023

May 13, 2023 at 02:54 am IST

Procaps Group S.A. provided earnings guidance for the fiscal year ending December 31, 2023. For the fiscal year ending December 31, 2023, the company expects net revenues at approximately 10%+ in 2023 on a constant currency basis.

Latest news about Procaps Group S.A.

Procaps Group S.A. Provides Earnings Guidance for the Year Ended December 31, 2023	02/05	CI
Procaps Group S.A. Announces Formation of Strategic Committee to Explore Value Creation Alternatives	04/03	CI
Procaps Group Announces Formation of Strategic Committee to Explore Value Creation Alternatives	04/03	CI
Hoche Partners Pharma Holding S A Issues a Letter to Procaps Group, S A	20/02	CI
Declaration of Voting Results by Procaps Group, S A	24/01	CI
Hoche Partners Sends a Letter to Procaps Group	13/01	CI
Procaps Group S.A. Provides Earnings Guidance for the Full Year 2023	27/12	CI
Procaps Group S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	27/12	CI
Tranche Update on Procaps Group S.A.'s Equity Buyback Plan announced on June 1, 2023.	27/12	CI
Procaps Group Teams Up With Genomma Lab to Manufacture, Market Softgel Products in Latin America	30/11	MT
Procaps Group and Genomma Lab Announce Strategic Agreement to Manufacture and Market Softgel Products in Latin America	30/11	CI
Procaps Group Names Jose Antonio Vieira as CEO	22/11	MT
Procaps Group S.A. Announces Executive Changes, Effective January 15, 2024	22/11	CI
Procaps Group S.A. Appoints Sandra Sanchez Y Oldenhage as A Director	24/23/24	CI
Transcript : Procaps Group S.A. - Special Call	10/23/10
Procaps Group S.A.(NasdaqGM:PROC) dropped from S&P Global BMI Index	18/23/18	CI
Procaps Group, S.A. Announces the Expansion of Its Oncology Portfolio	07/23/07	CI
Brookline Capital Downgrades Procaps to Hold From Buy, Price Target is $4.50	06/23/06	MT
Transcript : Procaps Group S.A., Q2 2023 Earnings Call, Sep 05, 2023	05/23/05
Earnings Flash (PROC) PROCAPS GROUP S.A. Posts Q2 Revenue $110M	05/23/05	MT
Procaps Group S.A. Announces Resignation of Mr. Alejandro Weinstein from the Board of Directors	05/23/05	CI
Procaps Group S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	05/23/05	CI
Procaps Group S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	06/23/06	CI
Procaps Group Q1 Earnings, Revenue Decline	06/23/06	MT
Procaps Group S.A. commences an Equity Buyback Plan for 11,282,418 shares, representing 10% of its issued share capital, under the plan approved on June 28, 2022.	01/23/01	CI

Chart Procaps Group S.A.

Duration

Period

More charts

Company Profile

Procaps Group SA is a Luxembourg-based healthcare and pharmaceutical company. The Company develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and high-potency clinical compounds. It operates its business through 5 units which are Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics provides diabetes solutions. Farma procaps formulates, manufactures and markets branded prescription drugs in Latin America. Softi Gel provides contract drug development and manufacturing services to third party pharmaceutical companies. Vital Care develops, manufactures and markets consumer healthcare products. Clinical Specialties develops, manufactures and markets complex drugs.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Procaps Group S.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.58 USD

Average target price

4.75 USD

Spread / Average Target

+84.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PROCAPS GROUP S.A.	-34.64%	291M
ELI LILLY AND COMPANY	+32.09%	694B
NOVO NORDISK A/S	+29.39%	593B
JOHNSON & JOHNSON	-1.34%	371B
MERCK & CO., INC.	+20.34%	331B
ABBVIE INC.	+7.39%	290B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	209B
NOVARTIS AG	+10.02%	209B
AMGEN INC.	+8.49%	169B

Other Pharmaceuticals

Procaps Group S.A.

Equities

PROC

LU2376511205

Pharmaceuticals

Procaps Group S.A. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2023

Latest news about Procaps Group S.A.

Chart Procaps Group S.A.

Company Profile

Income Statement Evolution

Ratings for Procaps Group S.A.

Analysts' Consensus

EPS Revisions

Quarterly revenue - Rate of surprise

Sector Other Pharmaceuticals